Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
==========
Gerresheimer CEO Dietmar Siemssen expects around 4% of the company's revenue growth per year to come from deals to supply makers of weight-loss and diabetes drugs with vials, cartridges, syringes, and autoinjectors. The company expects sales related to GLP-1 medicines to surpass 100 million euros this year and reach at least 350 million euros ($379 million) within the next three years. Analysts predict that Novo Nordisk's obesity drug Wegovy could bring in sales of about $8.6 billion this year and $12.86 billion in 2025, while Eli Lilly's Zepbound could generate sales of around $4 billion this year and $10.8 billion next year. The weight-loss drug market is expected to reach at least $100 billion by the end of the decade. Gerresheimer is already producing products for GLP-1 drugs in Germany and is ramping up a plant in Mexico for production. The company also manufactures pens for GLP-1 drugs in the Czech Republic, South America, and the U.S., and plans to produce them in China in the future. Gerresheimer recorded 1.99 billion euros ($2.15 billion) in sales last year and expects revenue growth of 5%-10% this year and 10%-15% in 2025.
#Gerresheimer #DietmarSiemssen #WeightlossDrugs #Glp1Drugs #Wegovy #Zepbound #ObesityDrugs #RevenueGrowth #Sales #DrugMarket